Rivaroxaban

"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Descriptor ID	D000069552
MeSH Number(s)	D02.886.778.727 D03.383.533.640.713 D03.383.903.727
Concept/Terms	Rivaroxaban Rivaroxaban 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide Xarelto Xarelto BAY 59-7939 BAY 59-7939 BAY 59 7939 BAY 597939

Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Sulfur Compounds [D02.886]
Thiophenes [D02.886.778]
Rivaroxaban [D02.886.778.727]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Oxazines [D03.383.533]
Morpholines [D03.383.533.640]
Rivaroxaban [D03.383.533.640.713]
Thiophenes [D03.383.903]
Rivaroxaban [D03.383.903.727]

Below are MeSH descriptors whose meaning is related to "Rivaroxaban".

Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.

Bar chart showing 23 publications over 13 distinct years, with a maximum of 6 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	0	2	2
2011	0	3	3
2012	0	1	1
2013	0	1	1
2014	0	1	1
2015	1	1	2
2016	5	1	6
2017	1	1	2
2018	1	0	1
2019	1	0	1
2020	1	0	1
2021	0	1	1
2022	1	0	1

Below are the most recent publications written about "Rivaroxaban" by people in Profiles.

Volod O, Rollins-Raval M, Goodwin AJ, Higgins RA, Long T, Chandler WL, Harris NS, Pham HP, Isom JA, Moser K, Olson JD, Smock KJ, VanSandt A, Wool G, Chen D. Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban. Arch Pathol Lab Med. 2022 01 02; 146(2):145-153.

View in: PubMed
Kline JA, Adler DH, Alanis N, Bledsoe JR, Courtney DM, d'Etienne JP, Diercks DB, Garrett JS, Jones AE, Mackenzie DC, Madsen T, Matuskowitz AJ, Mumma BE, Nordenholz KE, Pagenhardt J, Runyon MS, Stubblefield WB, Willoughby CB. Monotherapy Anticoagulation to Expedite Home Treatment of Patients Diagnosed With Venous Thromboembolism in the Emergency Department: A Pragmatic Effectiveness Trial. Circ Cardiovasc Qual Outcomes. 2021 07; 14(7):e007600.

View in: PubMed
Prentice A, Ruiz I, Weeda ER. Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis. J Thromb Thrombolysis. 2020 Apr; 49(3):360-364.

View in: PubMed
Ntaios G, Pearce LA, Meseguer E, Endres M, Amarenco P, Ozturk S, Lang W, Bornstein NM, Molina CA, Pagola J, Mundl H, Berkowitz SD, Liu YY, Sen S, Connolly SJ, Hart RG. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke. 2019 11; 50(11):3184-3190.

View in: PubMed
Coleman CI, Weeda ER, Nguyen E, Bunz TJ, Sood NA. Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018 10 01; 4(4):328-329.

View in: PubMed
Brodie MM, Newman JC, Smith T, Rockey DC. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. Am J Med. 2018 05; 131(5):573.e9-573.e15.

View in: PubMed
Weeda ER, Peacock WF, Fermann GJ, Baugh CW, Wells PS, Ashton V, Crivera C, Wildgoose P, Schein JR, Coleman CI. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).

View in: PubMed
Weeda ER, Wells PS, Peacock WF, Fermann GJ, Baugh CW, Ashton V, Crivera C, Wildgoose P, Schein JR, Coleman CI. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.

View in: PubMed
Weeda ER, Kohn CG, Peacock WF, Fermann GJ, Crivera C, Schein JR, Coleman CI. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.

View in: PubMed
Steed MB, Swanson MT. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know. Oral Maxillofac Surg Clin North Am. 2016 Nov; 28(4):515-521.

View in: PubMed

People

Explore

Similar Concepts

Top Journals